TrialClinical cancer research : an official journal of the American Association for Cancer Research2019

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.

Daniel Morgensztern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.